NCT02817802View on ClinicalTrials.gov

BIOTRONIKS - Safety and Performance in de NOvo Lesion of NatiVE Coronary Arteries With Magmaris- Registry: BIOSOLVE-IV

Active, not recruitingOBSERVATIONAL
Enrollment

2,066

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

July 14, 2020

Study Completion Date

October 31, 2025

Conditions
Coronary Artery Disease
Interventions
DEVICE

Magmaris

PCI (Magmaris)

Trial Locations (2)

2020

ZNA Middelheim Cardiologiy, Antwerp

Unknown

Queen Elizabeth Hospital, Kowloon

Sponsors

Lead Sponsor

Biotronik AG
All Listed Sponsors
lead

Biotronik AG

INDUSTRY

NCT02817802 - BIOTRONIKS - Safety and Performance in de NOvo Lesion of NatiVE Coronary Arteries With Magmaris- Registry: BIOSOLVE-IV | Biotech Hunter | Biotech Hunter